{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:49:30Z","timestamp":1789469370690,"version":"build-2803163510"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100015034","name":"Shahid Sadoughi University of Medical Sciences","doi-asserted-by":"publisher","award":["6672"],"award-info":[{"award-number":["6672"]}],"id":[{"id":"10.13039\/501100015034","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computers in Biology and Medicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.compbiomed.2023.107518","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T16:02:18Z","timestamp":1695830538000},"page":"107518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation"],"prefix":"10.1016","volume":"166","author":[{"given":"Saedeh","family":"Khadempar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Haghiralsadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massoud","family":"Saidijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Ghasemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5136-4259","authenticated-orcid":false,"given":"Saeid","family":"Afshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.compbiomed.2023.107518_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics","volume":"65","author":"Torre","year":"2012","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib2","article-title":"Investigating the effect of radiosensitizer for ursolic acid and Kamolonol acetate on HCT-116 cell line","volume":"28","author":"Abdali","year":"2020","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107518_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41575-019-0230-y","article-title":"Epigenetics of colorectal cancer: biomarker and therapeutic potential","volume":"17","author":"Jung","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib4","doi-asserted-by":"crossref","first-page":"327","DOI":"10.5217\/ir.2018.16.3.327","article-title":"Genetic and epigenetic alterations of colorectal cancer","volume":"16","author":"Hong","year":"2018","journal-title":"Intest. Res."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107518_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002020","article-title":"The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth","volume":"3","author":"Firestein","year":"2008","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107518_bib7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tips.2009.09.007","article-title":"HDAC2: a critical factor in health and disease","volume":"30","author":"Kr\u00e4mer","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib8","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1073\/pnas.1320850111","article-title":"Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and \u03b2-cell protection","volume":"111","author":"Christensen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.compbiomed.2023.107518_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118211","article-title":"Flavonoids potentiated anticancer activity of cisplatin in non-small cell lung cancer cells in vitro by inhibiting histone deacetylases","volume":"258","author":"Yan","year":"2020","journal-title":"Life Sci."},{"issue":"47","key":"10.1016\/j.compbiomed.2023.107518_bib10","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.17950","article-title":"HDAC inhibitors enhance the immunotherapy response of melanoma cells","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107518_bib11","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1016\/j.ejmech.2010.06.024","article-title":"Ligand and structure based pharmacophore modeling to facilitate novel histone deacetylase 8 inhibitor design","volume":"45","author":"Thangapandian","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107518_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/jcb.22185","article-title":"Histone deacetylase inhibitors: potential in cancer therapy","volume":"107","author":"Marks","year":"2009","journal-title":"J. Cell. Biochem."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib13","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.compbiomed.2023.107518_bib14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3389\/fonc.2018.00092","article-title":"Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi","volume":"8","author":"Suraweera","year":"2018","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.compbiomed.2023.107518_bib15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.csbj.2023.03.016","article-title":"HDAC2 as a target for developing anti-cancer drugs","volume":"13","author":"Jo","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107518_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3923\/tb.2013.25.44","article-title":"Breast cancer specific histone deacetylase inhibitors and lead discovery using molecular docking and descriptor study","volume":"6","author":"Sangeetha","year":"2013","journal-title":"Trends Bioinf."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107518_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/07391102.2019.1590241","article-title":"Combined pharmacophore modeling, 3D-QSAR and docking studies to identify novel HDAC inhibitors using drug repurposing","volume":"38","author":"Liu","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib18","first-page":"1","article-title":"Comprehensive prediction of drug-protein interactions and side effects for the human proteome","volume":"5","author":"Zhou","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2023.107518_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.605386","article-title":"Epidrug repurposing: discovering new faces of old acquaintances in cancer therapy","volume":"10","author":"Montalvo-Casimiro","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.compbiomed.2023.107518_bib20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-12-802808-7.00012-5","article-title":"Drug repurposing for epigenetic targets guided by computational methods","author":"Naveja","year":"2016","journal-title":"Epi-informatics"},{"issue":"D1","key":"10.1016\/j.compbiomed.2023.107518_bib21","doi-asserted-by":"crossref","first-page":"D1045","DOI":"10.1093\/nar\/gkv1072","article-title":"BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology","volume":"44","author":"Gilson","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2023.107518_bib22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.phymed.2017.11.012","article-title":"Predicting tyrosinase inhibition by 3D QSAR pharmacophore models and designing potential tyrosinase inhibitors from Traditional Chinese medicine database","volume":"38","author":"Gao","year":"2018","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1021\/jm010360c","article-title":"Pharmacophore mapping of a series of 2, 4-diamino-5-deazapteridine inhibitors of Mycobacterium avium complex dihydrofolate reductase","volume":"45","author":"Debnath","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107518_bib24","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.csbj.2019.02.006","article-title":"Ligand-based pharmacophore modeling, virtual screening and molecular docking studies for discovery of potential topoisomerase I inhibitors","volume":"17","author":"Pal","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ddtec.2004.11.015","article-title":"Pharmacophore definition and 3D searches","volume":"1","author":"Langer","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107518_bib26","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1021\/acs.jmedchem.0c01786","article-title":"US FDA approved drugs from 2015\u2013June 2020: a perspective","volume":"64","author":"Bhutani","year":"2021","journal-title":"J. Med. Chem."},{"issue":"D1","key":"10.1016\/j.compbiomed.2023.107518_bib27","doi-asserted-by":"crossref","first-page":"D1102","DOI":"10.1093\/nar\/gky1033","article-title":"PubChem 2019 update: improved access to chemical data","volume":"47","author":"Kim","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107518_bib28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"W1","key":"10.1016\/j.compbiomed.2023.107518_bib29","doi-asserted-by":"crossref","first-page":"W200","DOI":"10.1093\/nar\/gkv353","article-title":"FAF-Drugs3: a web server for compound property calculation and chemical library design","volume":"43","author":"Lagorce","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.compbiomed.2023.107518_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s10822-015-9887-7","article-title":"Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets","volume":"30","author":"Shahin","year":"2016","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1080\/07391102.2018.1434833","article-title":"Hierarchical virtual screening of the dual MMP-2\/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking","volume":"37","author":"Wang","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiomed.2023.107518_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113332","article-title":"Histone deacetylase 2: a potential therapeutic target for cancer and neurodegenerative disorders","volume":"216","author":"Gediya","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.compbiomed.2023.107518_bib33","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"Mark James Abraham","year":"2015","journal-title":"SoftwareX"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib34","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.3390\/molecules20033898","article-title":"Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents","volume":"20","author":"Mottamal","year":"2015","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107518_bib35","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107518_bib36","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1063\/1.328693","article-title":"Polymorphic transitions in single crystals: a new molecular dynamics method","volume":"52","author":"Parrinello","year":"1981","journal-title":"J. Appl. Phys."},{"issue":"5","key":"10.1016\/j.compbiomed.2023.107518_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expet Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.compbiomed.2023.107518_bib38","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1021\/ci500020m","article-title":"g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations","volume":"54","author":"Kumari","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.compbiomed.2023.107518_bib39","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00894-018-3858-6","article-title":"In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment","volume":"24","author":"Zarezade","year":"2018","journal-title":"J. Mol. Model."},{"issue":"4","key":"10.1016\/j.compbiomed.2023.107518_bib40","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212 \u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.compbiomed.2023.107518_bib41","first-page":"2014","article-title":"Ligand based pharmacophore modeling and virtual screening studies to design novel HDAC2 inhibitors","author":"Kandakatla","year":"2014","journal-title":"Adv. Bioinform."},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107518_bib42","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2174\/1386207319666160801154415","article-title":"Pharmacophore based 3D-QSAR, virtual screening and docking studies on novel series of HDAC inhibitors with thiophen linker as anticancer agents","volume":"19","author":"Patel","year":"2016","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.1016\/j.compbiomed.2023.107518_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.phymed.2018.09.199","article-title":"Pharmacophore-based drug design for the identification of novel butyrylcholinesterase inhibitors against Alzheimer\u2019s disease","volume":"54","author":"Jiang","year":"2019","journal-title":"Phytomedicine"},{"key":"10.1016\/j.compbiomed.2023.107518_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.compbiolchem.2018.01.005","article-title":"3D QSAR pharmacophore based virtual screening for identification of potential inhibitors for CDC25B","volume":"73","author":"Ma","year":"2018","journal-title":"Comput. Biol. Chem."},{"issue":"18","key":"10.1016\/j.compbiomed.2023.107518_bib45","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1080\/07391102.2018.1559098","article-title":"Pharmacophore-based virtual screening approach for identification of potent natural modulatory compounds of human Toll-like receptor 7","volume":"37","author":"Gupta","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107518_bib46","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/cmdc.202000805","article-title":"Do drug\u2010likeness rules apply to oral prodrugs?","volume":"16","author":"Protti","year":"2021","journal-title":"ChemMedChem"},{"issue":"W1","key":"10.1016\/j.compbiomed.2023.107518_bib47","doi-asserted-by":"crossref","first-page":"W200","DOI":"10.1093\/nar\/gkv353","article-title":"FAF-Drugs3: a web server for compound property calculation and chemical library design","volume":"43","author":"Lagorce","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"25","key":"10.1016\/j.compbiomed.2023.107518_bib48","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.compbiomed.2023.107518_bib49","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.compbiomed.2023.107518_bib50","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bbrc.2007.11.066","article-title":"Crystal structure of histone demethylase LSD1 and tranylcypromine at 2.25 \u00c5","volume":"366","author":"Mimasu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.compbiomed.2023.107518_bib52","doi-asserted-by":"crossref","first-page":"8635","DOI":"10.1016\/j.bmc.2008.08.003","article-title":"Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222","volume":"16","author":"Di Micco","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/cmdc.201300372","article-title":"Discovery of potent HDAC inhibitors based on chlamydocin with inhibitory effects on cell migration","volume":"9","author":"Wang","year":"2014","journal-title":"ChemMedChem"},{"issue":"13","key":"10.1016\/j.compbiomed.2023.107518_bib54","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1021\/jm2001025","article-title":"Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole-and pyrazole-based histone deacetylase probes","volume":"54","author":"Neelarapu","year":"2011","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib55","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-33024-2","article-title":"MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference","volume":"13","author":"Durojaye","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.compbiomed.2023.107518_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114523","article-title":"Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors","volume":"239","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiomed.2023.107518_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00894-018-3858-6","article-title":"In silico assessment of new progesterone receptor inhibitors using molecular dynamics: a new insight into breast cancer treatment","volume":"24","author":"Zarezade","year":"2018","journal-title":"J. Mol. Model."},{"issue":"2","key":"10.1016\/j.compbiomed.2023.107518_bib58","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2008.11.019","article-title":"HDAC inhibitors in models of inflammation-related tumorigenesis","volume":"280","author":"Glauben","year":"2009","journal-title":"Cancer Lett."},{"issue":"27","key":"10.1016\/j.compbiomed.2023.107518_bib59","doi-asserted-by":"crossref","first-page":"20436","DOI":"10.1074\/jbc.M000202200","article-title":"Histone deacetylases specifically down-regulate p53-dependent gene activation","volume":"275","author":"Juan","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"18","key":"10.1016\/j.compbiomed.2023.107518_bib60","doi-asserted-by":"crossref","DOI":"10.7150\/thno.26627","article-title":"Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling","volume":"8","author":"Huang","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.compbiomed.2023.107518_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-275","article-title":"Sp1 acetylation is associated with loss of DNA binding at promoters associated with cell cycle arrest and cell death in a colon cell line","volume":"9","author":"Waby","year":"2010","journal-title":"Mol. Cancer"},{"issue":"S1","key":"10.1016\/j.compbiomed.2023.107518_bib63","doi-asserted-by":"crossref","first-page":"89","DOI":"10.31557\/APJCP.2021.22.S1.89","volume":"22","author":"Sanaei","year":"2021","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/ars.2014.5863","article-title":"Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells","volume":"23","author":"Chueh","year":"2015","journal-title":"Antioxidants Redox Signal."},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107518_bib65","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1158\/1078-0432.CCR-15-2388","article-title":"c-Myc modulation and acetylation is a key HDAC inhibitor target in cancer","volume":"23","author":"Nebbioso","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.compbiomed.2023.107518_bib66","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/febs.15122","article-title":"Valproic acid targets HDAC1\/2 and HDAC1\/PTEN\/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer","volume":"287","author":"Sun","year":"2020","journal-title":"FEBS J."},{"issue":"41","key":"10.1016\/j.compbiomed.2023.107518_bib67","doi-asserted-by":"crossref","first-page":"35977","DOI":"10.1074\/jbc.M111.266254","article-title":"Pluripotency-related, valproic acid (VPA)-induced genome-wide histone H3 lysine 9 (H3K9) acetylation patterns in embryonic stem cells","volume":"286","author":"Hezroni","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.compbiomed.2023.107518_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/stem.1544","article-title":"Histone deacetylase inhibition with valproic acid downregulates osteocalcin gene expression in human dental pulp stem cells and osteoblasts: evidence for HDAC2 involvement","volume":"32","author":"Paino","year":"2014","journal-title":"Stem Cell."},{"issue":"7","key":"10.1016\/j.compbiomed.2023.107518_bib69","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1515\/hsz-2016-0307","article-title":"Valproic acid (VPA) enhances cisplatin sensitivity of non-small cell lung cancer cells via HDAC2 mediated down regulation of ABCA1","volume":"398","author":"Chen","year":"2017","journal-title":"Biol. Chem."}],"container-title":["Computers in Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523009836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010482523009836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:53:21Z","timestamp":1736362401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010482523009836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":69,"alternative-id":["S0010482523009836"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107518","relation":{},"ISSN":["0010-4825"],"issn-type":[{"value":"0010-4825","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lansoprazole as a potent HDAC2 inhibitor for treatment of colorectal cancer: An in-silico analysis and experimental validation","name":"articletitle","label":"Article Title"},{"value":"Computers in Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiomed.2023.107518","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107518"}}